Neuraminidase inhibitor resistance in influenza viruses - PubMed

Affiliations

• PMID: 17705169
• DOI: 10.1002/jmv.20951

Review

Neuraminidase inhibitor resistance in influenza viruses

Phillip Andrew Reece. J Med Virol. 2007 Oct.

Abstract

Zanamivir and oseltamivir, the currently marketed influenza virus neuraminidase inhibitors (NAIs), are prescribed for the treatment and prophylaxis of influenza and are being stockpiled for pandemic influenza. Oseltamivir resistance has been reported in up to 2% of patients in clinical trials of oseltamivir and in up to 18% of treated children. There are also reports in at least three patients treated with oseltamivir for influenza A (H5N1) infections. At this stage, there are no reports of resistance occurring to zanamivir in immunocompetent patients. Zanamivir and oseltamivir bind differently at the neuraminidase catalytic site and this contributes to different drug resistance profiles. The magnitude and duration of NAI concentrations at the site of infection are also expected to be important factors and are determined by route and timing of drug administration, dose, and pharmacokinetic differences between patients. In addition, the type, strain, and virulence of the influenza strain and the nature of the immune response all appear to play a role in determining the likelihood of drug resistance arising. The clinical significance of a particular NAI-resistant isolate from a patient is often not clear but virus viability and transmissibility are clearly important characteristics. Early initiation of NAI treatment in suspected cases of influenza is important for maximizing efficacy and minimizing the risk of drug resistance. Higher NAI doses and longer periods of treatment may be required for patients with influenza A (H5N1) infections but further work is needed in this area.

Similar articles

• Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

  Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H. Feng E, et al. ChemMedChem. 2012 Sep;7(9):1527-36. doi: 10.1002/cmdc.201200155. Epub 2012 Jul 16. ChemMedChem. 2012. PMID: 22807317 Review.

• [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

  Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F. Ferraris O, et al. Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. Pathol Biol (Paris). 2010. PMID: 20303677 Review. French.

• Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

  Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H. Dapat C, et al. Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17. Antiviral Res. 2013. PMID: 23791870

• Influenza viruses resistant to neuraminidase inhibitors.

  Nitsch-Osuch A, Brydak LB. Nitsch-Osuch A, et al. Acta Biochim Pol. 2014;61(3):505-8. Epub 2014 Sep 8. Acta Biochim Pol. 2014. PMID: 25195142 Review.

• Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.

  Hurt AC, Lowther S, Middleton D, Barr IG. Hurt AC, et al. Antiviral Res. 2010 Sep;87(3):361-6. doi: 10.1016/j.antiviral.2010.06.009. Epub 2010 Jul 21. Antiviral Res. 2010. PMID: 20603155

Cited by

• Human monoclonal antibodies broadly neutralizing against influenza B virus.

  Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T, Nishimura M, Misaki R, Kuhara M, Boonsathorn N, Fujiyama K, Okuno Y, Nakaya T, Ikuta K. Yasugi M, et al. PLoS Pathog. 2013 Feb;9(2):e1003150. doi: 10.1371/journal.ppat.1003150. Epub 2013 Feb 7. PLoS Pathog. 2013. PMID: 23408886 Free PMC article.

• Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence.

  Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA. Alymova IV, et al. Sci Rep. 2016 Oct 31;6:36216. doi: 10.1038/srep36216. Sci Rep. 2016. PMID: 27796371 Free PMC article.

• Avian influenza A/H5N1 neuraminidase expressed in yeast with a functional head domain.

  Yongkiettrakul S, Boonyapakron K, Jongkaewwattana A, Wanitchang A, Leartsakulpanich U, Chitnumsub P, Eurwilaichitr L, Yuthavong Y. Yongkiettrakul S, et al. J Virol Methods. 2009 Mar;156(1-2):44-51. doi: 10.1016/j.jviromet.2008.10.025. Epub 2008 Dec 11. J Virol Methods. 2009. PMID: 19038288 Free PMC article.

• Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.

  Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Wu JT, et al. PLoS Med. 2009 May 19;6(5):e1000085. doi: 10.1371/journal.pmed.1000085. Epub 2009 May 19. PLoS Med. 2009. PMID: 19440354 Free PMC article.

• Guidelines for identifying homologous recombination events in influenza A virus.

  Boni MF, de Jong MD, van Doorn HR, Holmes EC. Boni MF, et al. PLoS One. 2010 May 3;5(5):e10434. doi: 10.1371/journal.pone.0010434. PLoS One. 2010. PMID: 20454662 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley